Navigation Links
PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final
Date:2/28/2011

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the Technical Board of Appeal of the European Patent Office (EPO) has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's  European Patent No. 0 451 216B (the '216B Patent) overturned and the patent revoked. The effect of the termination of the opposition appeal proceeding is that the 2007 EPO decision upholding the claims of PDL's '216B Patent as valid will become the final decision of the EPO. The hearing was scheduled for February 28 and March 1, 2011.  In the year ended December 31, 2010, approximately 35 percent of PDL's revenues were derived from sales of products that were made in Europe and sold outside of the United States. These revenues could have been negatively impacted or eliminated entirely by an adverse ruling at the hearing.  

In an opposition proceeding brought by multiple parties, the Opposition Division of the EPO found in 2007 the claims of the '216B Patent to be valid. Five of the opposing parties filed notices of appeal to the Technical Board of Appeal of the EPO seeking to have the decision of the Opposition Division upholding the '216B Patent overturned and the patent revoked. Three of those parties filed detailed grounds of appeal:  UCB Pharma S.A., BioTransplant Incorporated whose counsel PDL believes has been financially supported by MedImmune LLC, and Novartis AG. Pursuant to PDL's recent settlements with UCB, MedImmune and Novartis, which were previously announced, and as a result of PDL's recent acquisition of BioTransplant out of bankruptcy and subsequent withdrawal of their appeal, all of the active appellants have formally withdrawn their participation in the appeal proceeding. Accordingly, the EPO cancelled the appeal hearing, terminated the opposition proceeding and
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PDL BioPharma Announces Regular Quarterly Dividend Policy
2. PDL BioPharma to Present at Upcoming Conferences
3. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
4. Success Factors and Failure Points in Biopharmaceutical Product Launches
5. Plato BioPharma, Inc Appoints New Board Member
6. UCB and PDL BioPharma Resolve Patent Disputes
7. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
8. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
9. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
10. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
11. Genesis Biopharma to Present at 2011 Biotech Showcase Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... and PRINCETON, N.J., Jan. 31, 2011 Qforma, the leading ... health sciences industry, today announced the appointments of Ted Pine ... Michael Murphy as Software Engineer. "As Qforma ... optimize service to our pharmaceutical industry customers, we welcome the ...
... 2011 OXIS International, Inc., (OTC Bulletin Board: ... favorable final results from an initial clinical study to ... joint health formula, launched commercially in December 2010. ... statistically significant after as little as one week of ...
Cached Medicine Technology:Qforma, Leading Provider of Healthcare Analytics, Announces Three New Appointments 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:9/16/2014)... Cliff Lake Dental Care is proud to announce the latest ... to join Dr. Rauchwarter's team. The team at Cliff Lake ... she will bring many benefits to the office as well ... Falls, WI. She finished dental assisting school and graduated ... assisting in the Twin Cities, Milwaukee, California and Virginia. ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT ... for its high morale and collaborative culture ... Firms to Work For 2014.” Consulting magazine publishes ... 10,000 consultants participating across all major industries, representing more ... conducted, and firms were ranked in six categories - ...
(Date:9/16/2014)... as part of breast conservation is the current ... (HR+) invasive breast cancer. A new study by ... that combination may not be necessary for all ... results, which Fox Chase researchers presented at the ... on Sunday, September 14, suggest that low-risk patients ...
(Date:9/16/2014)... September 16, 2014 Seven heroes who ... world will be honored in New York City on ... ), the only global recognition and funding program that ... by the media as the “Nobel Prize for Child ... created life-changing programs that benefit children in countries around ...
(Date:9/16/2014)... Los Angeles, CA (PRWEB) September 16, 2014 ... the League of United Latin American Citizens (LULAC) will ... California. LULAC’s Feria de Salud will feature free health ... Other free testing includes glucose and cholesterol levels ... screenings will be available for children under 6 years ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2
... BRIDGEWATER, N.J., March 16 Sanofi-aventis U.S. announced ... to Chief Science Officer/Chief Medical Officer, U.S., effective ... sanofi-aventis, U.S. As the company,s Chief Science ... establish a unified medical voice for sanofi-aventis U.S. ...
... Training and Professional Certification ProgramsKERRY, Ireland and ... leading Ireland-based provider of innovative learning solutions, ... eLearning and certification programs for the American ... the Insurance Institute of America (the Institutes), ...
... result, studies find, , , MONDAY, March 16 (HealthDay News) ... can be successfully harnessed to deliver health information to ... encouraging them to stick more closely to the treatments ... suggests. , One study explored giving teens regular ...
... (NYSE: MHS ) Chairman and CEO David ... Luncheon Address to the American Enterprise Institute,s health care ... March 18, 2009, at 12:30 p.m. Through the ... be directed at expanding the use of health information ...
... Vitamin D, but be Careful Not to Burn Cautions Tanning ... Indoor Tanning Association (ITA) is encouraging beach goers to tan ... good health, overexposure to UV light can be a dangerous ... order for tanners to get all the benefits of UV ...
... the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid ... 14. Notable updates include a new page on Thyroid ... molecule kinase inhibitors, and revised procedures for evaluating thyroid ... of Texas M.D. Anderson Cancer Center and chair ...
Cached Medicine News:Health News:Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer 2Health News:Ireland's PulseLearning Inks Agreement With Leading U.S. Insurance Industry Association 2Health News:Using Music and Sports to Improve Kids' Asthma 2Health News:Using Music and Sports to Improve Kids' Asthma 3Health News:Media Advisory: Medco CEO David B. Snow Jr. To Address American Enterprise Institute: 'Health IT: Empowering Precision Medicine' 2Health News:Indoor Tanning Association Promotes Responsible Tanning for Spring Breakers 2Health News:NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma 2Health News:NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma 3Health News:NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma 4
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: